PBI-4425, a Novel Anti-Inflammatory/Fibrotic CompoundThe 2015 ANS abstracts supplement is out...PLI has even more papers than last year (mostly new stuff)...I'm still going through the document (1129 pages..this is where the CTRL+F function gets useful : ) and there is at least 5 abstracts related to PBI-4xxx family.
For those interested, click on the following link :
https://www.asn-online.org/education/kidneyweek/archives/
and then on "
Abstract Supplement (PDF, 42.8MB)"
After PBI-4547 last year, it's PBI-4425 turns this year : "
PBI-4425, a Novel Anti-Inflammatory/Fibrotic Compound, Improves Kidney Function and Structure in the Diabetic db/db Mouse Model" (see page 713).
At page 244, the pharmacokinetoc profile of PBI-4050 is shown. This is actually the phase 1 (and 1b on CDK patients) detailed results. Half-time of PBI-4050 in the body goes from 3.5h to 5h depending on the dose (mg).
All there CKD results are great, but I'm almost more curious to see the results on the cardiac fibrosis side...that they will published at the AHA 2015 (also next month). Huge market ($ and in term of visibility) for an efficient oral treatment...
M80